Plant Name: Vitex negundo
Taxonomic Information:
Plant ID: NPO14602
Plant Latin Name: Vitex negundo
Taxonomy Genus: Vitex
Taxonomy Family: Lamiaceae
Plant External Links:
NCBI TaxonomyDB:
361442
Plant-of-the-World-Online:
865894-1
Used in Medicines:
Country/Region:
Pakistan; Guinea; Philippines; Indonesia; India; Malaysia; Vietnam; China; Sri Lanka; ThailandTraditional Medicine System:
Sowa-Rigpa; Indian Folk; Unani; Siddha; Ayurveda; TCMMedicinal Functions:
Antibacterial; Antitumor; Astringent; Expectorant; Febrifuge; Sedative; Tonic; Vermifuge
Geographical Distribution:
Afghanistan; Madagascar; Bangladesh; Guinea; Nepal; Cambodia; Somalia; Iran; Cuba; China; Thailand; Haiti; Tanzania; Maldives; Philippines; Indonesia; Mauritius; Trinidad and Tobago; Vietnam; Pakistan; Myanmar; South Africa; India; Malaysia; Mozambique; Sri Lanka; Japan; Taiwan; United States
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADORA3; ADORA2A; ADORA1; FFAR1; FFAR4; HCAR2; | |
| TSHR; NPSR1; | |
| ALPL; TDP1; BLM; ADK; TK1; HSD11B1; AKR1B10; ALOX12; AKR1B1; HSD17B10; NOX4; ALOX15; AOX1; POLB; | |
| AURKB; MET; AXL; FLT3; CDK1; MAPK1; EGFR; PIM1; KDR; IGF1R; | |
| CA2; CA9; CA14; CA7; CA4; CA12; | |
| PPARA; | |
| ESR1; ESR2; | |
| ESRRB; ESRRA; | |
| KDM4E; | |
| MMP12; MMP9; MMP1; MMP2; | |
| HIF1A; TP53; NFKB1; | |
| FUT7; | |
| LMNA; FABP3; FABP5; FABP4; APP; | |
| L3MBTL1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | TK1 | Thymidine kinase, cytosolic | P04183 | CHEMBL2883 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | HCAR2 | Hydroxycarboxylic acid receptor 2 | Q8TDS4 | CHEMBL3785 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.771E-12 | 1.642E-08 | CA12, CA14, CA2, CA4, CA7, CA9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 3.404E-11 | 4.941E-08 | BLM, CA12, CA2, CA4, CA7, CA9, ESR1, ESR2, ESRRA, ESRRB, L3MBTL1, MMP1, MMP12, MMP2, MMP9, PPARA, TK1, TP53 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.955E-09 | 2.509E-06 | CA12, CA14, CA2, CA4, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 9.291E-08 | 2.561E-05 | CA12, CA2, CA4, CA7, CA9 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.368E-07 | 3.385E-05 | ALPL, APP, BLM, CYP1B1, EGFR, ESR1, FLT3, MAPK1, NFKB1, NOX4 |
| MF | Unclassified; | GO:0004872; receptor activity | 1.623E-07 | 3.841E-05 | ADORA1, ADORA2A, ADORA3, AXL, EGFR, ESR1, ESR2, ESRRA, ESRRB, FFAR1, FFAR4, FLT3, HCAR2, IGF1R, KDR, MET, NPSR1, PPARA, TSHR |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.048E-06 | 2.001E-04 | AKR1B1, AKR1B10, APP, CYP19A1, CYP1B1, CYP2C9, ESR1, HSD11B1 |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 1.039E-06 | 2.001E-04 | ADORA1, ADORA2A, ADORA3 |
| MF | GO:0005488; binding | GO:0005504; fatty acid binding | 1.496E-06 | 2.692E-04 | FABP3, FABP4, FABP5, FFAR4 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 1.661E-06 | 2.940E-04 | ADORA1, ADORA2A, CYP19A1, FFAR4, NFKB1, PPARA |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 2.199E-06 | 3.770E-04 | ALPL, AXL, CA2, CA9, EGFR, ESR1, ESRRA, FABP3, FFAR1, FLT3, NFKB1, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0048143; astrocyte activation | 2.483E-06 | 4.092E-04 | ADORA2A, APP, EGFR |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 2.483E-06 | 4.092E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0023052; signaling | GO:0046887; positive regulation of hormone secretion | 2.702E-06 | 4.390E-04 | ADORA2A, CYP19A1, EGFR, FFAR1, HCAR2, HIF1A |
| BP | GO:0002376; immune system process | GO:0002682; regulation of immune system process | 3.300E-06 | 5.284E-04 | ADORA1, ADORA2A, ALOX15, APP, AXL, CA2, CYP19A1, ESR1, ESRRA, HCAR2, HIF1A, L3MBTL1, MAPK1, MMP12, MMP2, NFKB1, TP53 |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 7.606E-06 | 1.112E-03 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 7.598E-06 | 1.112E-03 | ADORA2A, AOX1, APP, BLM, EGFR, ESR1, ESR2, FLT3, IGF1R, KDR, L3MBTL1, MAPK1, MET, MMP9, NFKB1, TK1, TP53 |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 8.380E-06 | 1.216E-03 | ADORA2A, CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 9.810E-06 | 1.352E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 9.810E-06 | 1.352E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 9.810E-06 | 1.352E-03 | ALOX12, ALOX15 |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 1.121E-05 | 1.516E-03 | CDK1, ESR1, ESR2, ESRRA, ESRRB, PPARA |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.121E-05 | 1.516E-03 | ALOX12, ALOX15, AOX1, CYP19A1, CYP1B1, CYP2C9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.217E-05 | 1.636E-03 | CYP19A1, CYP1B1, CYP2C9, NOX4 |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 1.691E-05 | 2.116E-03 | ADORA1, HIF1A, LMNA, MMP2, NOX4, PPARA, TP53 |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 1.865E-05 | 2.309E-03 | ESR1, ESR2, ESRRA, ESRRB, PIM1, PPARA |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 2.009E-05 | 2.472E-03 | AKR1B1, AKR1B10, ALOX12, ALOX15, AOX1, CYP19A1, CYP1B1, CYP2C9, HSD11B1, HSD17B10, KDM4E, NOX4 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 2.109E-05 | 2.549E-03 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 2.631E-05 | 3.031E-03 | ADORA1, CA2, CA4, CA9, EGFR, TSHR |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.937E-05 | 3.182E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 2.937E-05 | 3.182E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 2.937E-05 | 3.182E-03 | ALOX12, ALOX15 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 2.937E-05 | 3.182E-03 | ADORA1, ADORA2A |
| BP | GO:0032501; multicellular organismal process | GO:0001503; ossification | 2.997E-05 | 3.218E-03 | ALOX15, ALPL, EGFR, MMP2, MMP9 |
| BP | GO:0022414; reproductive process | GO:0001892; embryonic placenta development | 3.288E-05 | 3.361E-03 | EGFR, ESRRB, HIF1A |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 3.632E-05 | 3.628E-03 | ALOX15, APP, EGFR, FFAR4, KDR, NOX4 |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 4.105E-05 | 4.063E-03 | AKR1B1, AXL, CDK1, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:1901653; cellular response to peptide | 4.919E-05 | 4.616E-03 | AKR1B1, APP, IGF1R, NFKB1, TP53, TSHR |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 4.919E-05 | 4.616E-03 | ADORA1, ADORA2A, CA2, CA7, KDR, NPSR1 |
| BP | GO:0050896; response to stimulus | GO:0009314; response to radiation | 5.192E-05 | 4.737E-03 | APP, AURKB, BLM, EGFR, HIF1A, NOX4, POLB, TP53 |
| MF | GO:0005488; binding | GO:0044877; macromolecular complex binding | 5.221E-05 | 4.737E-03 | ADORA1, EGFR, ESRRB, FLT3, IGF1R, KDR, L3MBTL1, MMP12, MMP9, PIM1, PPARA, TSHR |
| BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 5.276E-05 | 4.747E-03 | MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 5.622E-05 | 4.976E-03 | ESR1, ESR2, ESRRA, ESRRB, PPARA |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 5.862E-05 | 5.126E-03 | ESR1, ESR2 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 6.559E-05 | 5.601E-03 | FABP3, FABP4, FABP5 |
| BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 9.659E-05 | 7.777E-03 | ADORA2A, EGFR, FFAR1, HCAR2, HIF1A, MMP12 |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 9.743E-05 | 7.777E-03 | AXL, CDK1, EGFR, FLT3 |
| BP | GO:0008283; cell proliferation | GO:0048661; positive regulation of smooth muscle cell proliferation | 9.743E-05 | 7.777E-03 | AKR1B1, EGFR, MMP2, MMP9 |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 9.750E-05 | 7.777E-03 | ALOX12, ALOX15 |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 1.025E-04 | 8.135E-03 | ALOX15, EGFR, PPARA, TP53 |
| BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 1.133E-04 | 8.779E-03 | MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0009987; cellular process | GO:0071345; cellular response to cytokine stimulus | 1.242E-04 | 9.553E-03 | ALOX15, AXL, FABP4, FLT3, HIF1A, MAPK1, NFKB1 |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 1.265E-04 | 9.596E-03 | EGFR, MAPK1, MMP9 |
| BP | GO:0009987; cellular process | GO:0010638; positive regulation of organelle organization | 1.270E-04 | 9.600E-03 | ALOX15, AURKB, HIF1A, KDR, MAPK1, MET, MMP9, NOX4, TP53 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 5.343E-10 | 4.515E-08 | MMP2, KDR, MAPK1, TP53, HIF1A, ESR1, MMP9, MET, EGFR, IGF1R |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 7.538E-12 | 1.274E-09 | CA12, CA2, CA4, CA7, CA9, CA14 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 2.588E-09 | 1.458E-07 | MMP1, MMP2, MAPK1, MMP9, TP53, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 2.819E-08 | 1.191E-06 | FLT3, MMP1, MMP2, MAPK1, HIF1A, MET, TP53, MMP9, EGFR, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 5.402E-08 | 1.826E-06 | FLT3, MAPK1, TP53, MET, HIF1A, EGFR |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 5.624E-07 | 1.584E-05 | MMP2, MAPK1, ESR1, MMP9, EGFR, ESR2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 2.406E-06 | 4.678E-05 | HCAR2, ADORA2A, ADORA1, MAPK1, PPARA, NFKB1, TSHR |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 2.491E-06 | 4.678E-05 | MAPK1, TP53, MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 3.202E-06 | 5.412E-05 | PIM1, CYP1B1, MAPK1, TP53, MMP9, MET, EGFR, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 2.160E-06 | 4.678E-05 | FABP3, FABP4, FABP5, MMP1, PPARA |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 7.615E-06 | 1.170E-04 | MAPK1, TP53, EGFR, NFKB1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.554E-05 | 2.189E-04 | MAPK1, HIF1A, EGFR, NFKB1, IGF1R |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 2.333E-05 | 2.816E-04 | CYP2C9, APP, ALOX15, MAPK1, ALOX12 |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 1.801E-05 | 2.341E-04 | FLT3, TP53, MMP9, MET, NFKB1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 4.397E-05 | 4.331E-04 | ADORA2A, KDR, MAPK1, MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 2.741E-05 | 3.088E-04 | FLT3, PIM1, MAPK1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 4.613E-05 | 4.331E-04 | MAPK1, TP53, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 3.253E-05 | 3.436E-04 | ADORA3, ADORA1, MAPK1, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 6.599E-05 | 5.270E-04 | KDR, MAPK1, MET, EGFR, NFKB1, IGF1R |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 7.490E-05 | 5.270E-04 | ALOX15, ADK, AKR1B1, ALOX12, CYP19A1, HSD17B10, HSD11B1, CYP2C9, FUT7, AKR1B10, ALPL, AOX1, TK1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 7.796E-05 | 5.270E-04 | KDR, MAPK1, TP53, MET, EGFR, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 4.900E-05 | 4.358E-04 | MAPK1, TP53, EGFR, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 5.322E-05 | 4.497E-04 | MAPK1, PPARA, TP53, EGFR, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 6.899E-05 | 5.270E-04 | MAPK1, ESR1, NFKB1, ESR2 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.563E-04 | 1.666E-03 | MMP2, PIM1, MAPK1, NFKB1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 7.681E-05 | 5.270E-04 | MAPK1, MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 4.023E-04 | 2.428E-03 | POLB, CDK1, MAPK1, TP53, NFKB1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 3.760E-04 | 2.354E-03 | KDR, MAPK1, MET, EGFR, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 4.636E-04 | 2.691E-03 | MAPK1, TP53, ESR1, HIF1A |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 8.810E-04 | 4.217E-03 | LMNA, MAPK1, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 1.030E-03 | 4.704E-03 | MAPK1, TP53, MMP9, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 6.670E-04 | 3.416E-03 | MAPK1, TP53, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 5.364E-04 | 2.924E-03 | MAPK1, TP53, EGFR |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 6.670E-04 | 3.416E-03 | FABP4, ADORA1, TSHR |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 4.778E-04 | 2.691E-03 | CYP1B1, CYP19A1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 1.442E-03 | 5.946E-03 | MAPK1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 1.077E-03 | 4.792E-03 | MAPK1, MET, HIF1A |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 8.983E-04 | 4.217E-03 | CYP2C9, ALOX15, ALOX12 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 1.175E-03 | 5.091E-03 | MET, EGFR, NFKB1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 7.392E-04 | 3.674E-03 | HSD11B1, CYP1B1, CYP19A1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.442E-03 | 5.946E-03 | HSD11B1, CYP2C9, CYP1B1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 2.464E-03 | 9.464E-03 | CDK1, MAPK1, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 2.014E-03 | 8.106E-03 | HSD11B1, CYP2C9, CYP1B1 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 2.221E-03 | 8.731E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; HCAR2; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| I00-I99: Diseases of the circulatory system | Acute ischemic stroke | I61-I63 | HCAR2; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; TK1; TP53; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; PIM1; MET; CDK1; IGF1R; KDR; NFKB1; FLT3; TK1; HIF1A; ADORA3; MMP9; MAPK1; EGFR; TP53; MMP2; APP; CA9; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1; |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
| A00-B99: Certain infectious and parasitic diseases | Adult varicella zoster virus infection | B02 | TK1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ESRRA; AKR1B1; MMP1; |
| NA: NA | Geographic retinal atrophy | NA | APP; |
| NA: NA | GIST | NA | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HCAR2; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP; |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; ADORA2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HSD11B1; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; EGFR; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; EGFR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
| NA: NA | Menopausal disorder | NA | ESR1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | APP; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; TK1; HIF1A; MMP9; MAPK1; EGFR; TP53; MMP2; CA9; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK; |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; EGFR; AKR1B1; TP53; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; FLT3; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; FLT3; TK1; EGFR; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Graft-versus-host disease | T86.0 | TK1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; EGFR; CA9; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; MMP2; |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A; ESRRA; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; TP53; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA1; ADORA2A; ADORA3; AKR1B1; |
| NA: NA | Gonorrheal vaginitis | NA | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; MMP2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1; ESRRA; FFAR1; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A; |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA; EGFR; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; MMP2; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; CA9; |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1; |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; ADORA1; HCAR2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | ESRRA; |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HSD11B1; NFKB1; HCAR2; FFAR1; |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; CDK1; IGF1R; KDR; FLT3; EGFR; CYP19A1; CA9; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HSD11B1; ADORA1; AKR1B1; FFAR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | ESRRA; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA1; ADORA2A; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; HSD11B1; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A; EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; IGF1R; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; APP; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; CDK1; IGF1R; ADORA2A; ADK; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ADORA1; ADORA2A; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; ADORA3; |
| NA: NA | Hepatitis C virus infection | NA | ADORA3; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR; ALPL; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; MMP9; EGFR; TP53; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; HSD11B1; HCAR2; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; ADORA1; ADORA2A; ESRRA; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A; HCAR2; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; ESRRA; MMP2; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; ADORA1; |
| NA: NA | Edema | NA | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA1; ADORA2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ESRRA; MMP1; |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; CYP19A1; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; EGFR; MMP2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; EGFR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ADORA1; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ADORA1; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP; |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
| NA: NA | Postmenopausal disorder | NA | ESR1; |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; TK1; EGFR; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; EGFR; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; NPSR1; APP; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; TK1; EGFR; MMP2; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
